摘要
目的观察硼替佐米治疗多发性骨髓瘤(MM)的临床疗效及其对炎性反应、肾功能及免疫功能的影响。方法选取2020年5月—2021年7月抚州市第一人民医院收治的MM患者60例,按照随机数字表法分为常规治疗组与硼替佐米组,各30例。常规治疗组予以常规化疗,硼替佐米组在常规治疗组基础上加用注射用硼替佐米,2组均持续治疗4个疗程。比较2组临床疗效、治疗前及治疗4个疗程后血清炎性因子[C反应蛋白(CRP)、肿瘤坏死因子α(TNF-α)]、肾功能指标[血肌酐(SCr)、血尿素氮(BUN)]、免疫功能指标(CD_(3)^(+)、CD_(4)^(+)、CD_(8)^(+)),不良反应。结果硼替佐米组治疗总有效率为83.33%,高于常规治疗组的53.33%(χ^(2)=6.239,P=0.012)。2组治疗4个疗程后,血清CRP、TNF-α、SCr、BUN水平较治疗前降低,且硼替佐米组低于常规治疗组(P<0.01)。治疗4个疗程后,2组CD_(3)^(+)、CD_(4)^(+)高于治疗前,CD_(8)^(+)低于治疗前,且硼替佐米组CD_(3)^(+)、CD_(4)^(+)高于常规治疗组,CD_(8)^(+)低于常规治疗组(P<0.01)。2组不良反应总发生率比较,差异无统计学意义(P>0.05)。结论硼替佐米治疗MM的临床疗效确切,可有效改善患者免疫功能,减轻炎性反应,提高肾功能,且安全性较高。
Objective To observe clinical effect of bortezomib in the treatment of MM and its effect on inflammatory response,renal function and immune function.Methods A total of 60 cases of patients with MM were selected from May 2020 to July 2021 in First People′s Hospital of Fuzhou,which were divided into into conventional treatment group and bortezomib group according to the random number table method,30 cases in each group.The conventional treatment group was given conventional chemotherapy,while the bortezomib group was given bortezomib for injection on the basis of the conventional treatment group.Both groups were treated continuously for 4 courses.Clinical efficacy,inflammatory factors(CRP,TNF-α),renal function indexes(SCr,BUN),immune function indexes(CD_(3)^(+),CD_(4)^(+),CD_(8)^(+))before and after 4 courses of treatment were compared between the two groups,and the incidence of adverse reactions were observed.Results The total effective rate of bortezomib group was 83.33%,which was higher than 53.33%of conventional treatment group(χ^(2)=6.239,P=0.012).After 4 courses of treatment,the serum levels of CRP,TNF-α,SCr and BUN in the two groups were lower than those before treatment(P<0.01);after 4 courses of treatment,the serum levels of CRP,TNF-α,SCr and BUN in bortezomib group were lower than those in conventional treatment group(P<0.01).After 4 courses of treatment,CD_(3)^(+)and CD_(4)^(+)in the two groups were higher than those before treatment,CD_(8)^(+)was lower than that before treatment,and CD_(3)^(+)and CD_(4)^(+)in bortezomib group were higher than those in conventional treatment group,but CD_(8)^(+)was lower than that in conventional treatment group(P<0.01).There was no significant difference in the total incidence of adverse reactions between the two groups(P>0.05).Conclusion Bortezomib is effective in the treatment of MM,which can effectively improve the immune function of patients,reduce inflammatory reaction and promote renal function,and with high safety.
作者
吴仲林
龚菊萍
王淑芳
WU Zhonglin;GONG Juping;WANG Shufang(Department of Hematology,First People′s Hospital of Fuzhou,Fuzhou 344000,China)
出处
《临床合理用药杂志》
2022年第36期17-19,26,共4页
Chinese Journal of Clinical Rational Drug Use
关键词
多发性骨髓瘤
硼替佐米
免疫功能
炎性反应
肾功能
Multiple myeloma
Bortezomi
Immunologic function
Inflammatory reaction
Renal function
